REGENXBIO unveils new gene therapy data and manufacturing advances at ASGCT 2026 conference.

REGENXBIO announced presentations at the 2026 ASGCT meeting showcasing advancements in their NAVXpress manufacturing platform and pivotal data from RGX-202, a gene therapy for Duchenne muscular dystrophy. The company also highlighted research on next-generation gene therapies for rare and retinal diseases, including novel AAV capsids with improved targeting and reduced side effects. These updates reinforce REGENXBIO's leadership in gene therapy innovation and its potential to transform treatment for rare genetic disorders.